# STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant

Study · id `cardio:ct-nct06901466` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06901466](<https://clinicaltrials.gov/study/NCT06901466>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06901466

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Heart failure; Valve and congenital heart disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 880 participants.

## Technical summary

Registry record NCT06901466. Randomized; no masking; primary purpose treatment. Start 2025-06-13 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 880 participants (planned count; ClinicalTrials.gov record NCT06901466, source copy `cardio:ctgov-nct06901466-2026-03-09`, retrieved 2026-10-26)
- Started: 2025-06-13 (actual) (ClinicalTrials.gov record NCT06901466, source copy `cardio:ctgov-nct06901466-2026-03-09`, retrieved 2026-10-26)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06901466, source copy `cardio:ctgov-nct06901466-2026-03-09`, retrieved 2026-10-26)
- Completion: 2028-10-31 (anticipated) (ClinicalTrials.gov record NCT06901466, source copy `cardio:ctgov-nct06901466-2026-03-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06901466, source copy `cardio:ctgov-nct06901466-2026-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06901466-2026-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
- Acronym: STAR-TEER Ⅰ
- Condition: Mitral Regurgitation
- Intervention (Drug): Experimental: Rivaroxaban monotherapy
- Intervention (Drug): Active Comparator: Rivaroxaban+Clopidogrel
- Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital (`cardio:org-chinese-academy-of-medical-sciences-fuwai-hospital`)

## Provenance

Content hash: 93393dac5025710dbca404124ea5d218ebb22d96d6599e245486e0895961a6e4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
